微芯生物：透脑Aurora B选择性抑制剂CS231295片美国IND获FDA批准

Core Viewpoint - Microchip Biotech announced that its wholly-owned subsidiary, Microchip Biotech (USA) LLC, has received FDA approval for the clinical trial application (IND) of its next-generation brain-penetrating Aurora B selective inhibitor CS231295 tablets for the treatment of advanced solid tumors. This marks the first drug of its kind to enter clinical trials globally [1]. Group 1 - The drug CS231295 is designed specifically for the treatment of advanced solid tumors [1]. - The FDA approval signifies a significant milestone for the company and the potential for innovative treatment options in oncology [1]. - There are currently no other drugs with a similar design in clinical trial stages worldwide [1].